Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer

NCT00203424 is registered in ClinicalTrials.gov with Translational Oncology Research International as lead sponsor.

NCT NCT00203424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00203424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Lead sponsor
Translational Oncology Research International
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
June 30, 2010
Enrollment
23 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer